Park Hyun Jun, Moon Kyung Hyun, Lee Seung Wook, Lee Won Ki, Kam Sung Chul, Lee Jun Ho, Park Nam Cheol
Department of Urology, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
World J Mens Health. 2014 Apr;32(1):18-27. doi: 10.5534/wjmh.2014.32.1.18. Epub 2014 Apr 25.
Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly used treatment for erectile dysfunction (ED). Since the launch of sildenafil, several drugs-including mirodenafil, sildenafil citrate (sildenafil), tadalafil, vardenafil HCL (vardenafil), udenafil, and avanafil-have become available. Mirodenafil is a newly developed pyrrolopyrimidinone compound, which is a potent, reversible, and selective oral PDE5 inhibitor. Mirodenafil was launched in Korea in 2007, and an orally disintegrating film of mirodenafil was developed in 2011 for benefitting patients having difficulty in swallowing tablets. This study aimed to review the pharmacokinetic characteristic profile of mirodenafil and report evidence on its efficacy in the case of ED. In addition, we reviewed randomized controlled studies of mirodenafil's daily administration and efficacy for lower urinary tract symptoms.
5型磷酸二酯酶（PDE5）抑制剂是治疗勃起功能障碍（ED）最常用的药物。自西地那非上市以来，包括米罗地那非、枸橼酸西地那非（西地那非）、他达拉非、盐酸伐地那非（伐地那非）、乌地那非和阿伐那非在内的几种药物已可供使用。米罗地那非是一种新开发的吡咯并嘧啶酮化合物，是一种强效、可逆且选择性的口服PDE5抑制剂。米罗地那非于2007年在韩国上市，并于2011年开发出米罗地那非口腔崩解膜，以造福吞咽片剂有困难的患者。本研究旨在回顾米罗地那非的药代动力学特征，并报告其在ED病例中的疗效证据。此外，我们还回顾了米罗地那非每日给药及对下尿路症状疗效的随机对照研究。
